UnknownNot Applicable

Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient

Egypt100 participantsStarted 2020-12-01

Plain-language summary

polymorphisms of drug transporter genes may influence of Doxorubicin-Cyclophosphamide toxicity in breast cancer patients. the investigators want to evaluate the association between associations between genetic polymorphisms of ABCB1,SLC22A16 Genes and Toxicity of Doxorubicin and Cyclophosphamide Chemotherapy in Breast Cancer Patients treated by Doxorubicin-Cyclophosphamide regimen therapy

Who can participate

Age range20 Years – 75 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. women who has confirmed diagnosis of breast cancer.
✓. patient who will be treated with cyclophosphamide and doxorubicin(AC) regimen only .
✓. patient take drug regimen for first time.

What they're measuring

.1-The frequency of the genetic polymorphisms of ABCB1 in breast cancer patien

Timeframe: up to 24 week

The frequency of the genetic polymorphisms of SLC22A16 in breast cancer patients

Timeframe: up to 24 week

Trial details

NCT IDNCT04654195

SponsorDamanhour University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-02-01

Contact for this trial

Hoda salem, Ass.prof

002010000007613 hsalem@ut.edu.sa

View on ClinicalTrials.gov More Breast Cancer Patients trials